Biotech IPOs Outperform AI Listings Amid Sector Rotation

Biotechnology and pharmaceutical initial public offerings are currently dominating the U.S. market, delivering a weighted average return of 55%, according to data compiled by Bloomberg as reported by the Financial Post. This performance stands in sharp contrast to the broader U.S. IPO market, which has seen a weighted average loss of 4.4%.

While 2026 was expected to be defined by aerospace, defense, and AI listings, the ten largest U.S. deals of the year have seen shares slump by a weighted average of 6.3%. This decline comes as investors question if the AI rally has become overextended. In contrast, the Nasdaq Biotechnology index has gained 13% this year.

Several factors are driving this biotech surge, including notable trial data breakthroughs, a more stable regulatory environment, and significant acquisitions by large pharmaceutical firms. The Financial Post notes three recent buyouts valued at US$10 billion or more: Abbvie Inc.’s purchase of Apogee Therapeutics Inc., GSK PLC’s acquisition of Nuvalent Inc., and Vertex Pharmaceuticals Inc.’s acquisition of Crinetics Pharmaceuticals Inc. These deals have increased valuations and provided investors with cash to reinvest in the IPO market.

Industry leaders indicate a shift in capital allocation. Seth Rubin, global head of ECM at Stifel Financial Corp., stated that some of the world's largest fund families are reallocating more capital into healthcare. Jack Bannister, senior managing director in equity capital markets at Leerink Partners, described the current environment as the healthiest biotech IPO market in a long time.

This momentum is fueling a steady stream of summer debuts. At least six biotech companies, including CRISPR-based genetic medicines developer Scribe Therapeutics Inc., filed for IPOs this month, with pricing expected through the first half of August.